Sorry bro but after this I'm done with this thread. I can tell by your last question that you never read the guides I wrote and posted at: http://anabolicminds.com/forum/igf-1...dat-s-cjc.html
Why bother arguing with someone about something which is a basic established fact. GHRPs have a low oral bioavailability. They are orally bioavailabe...but not highly so. The oral bioavailability is less then 1%. There are studies where it was administered orally at I believe 25mg per dose.
They are also bioavailable via intranasal administration.
Again the dose has to be much higher than that used by injection.
Did you read the complete study you posted?
They used subcutaneous injection not oral administration.
Here this is from the "Subjects and Methods" section of that study:
Parents were instructed in sc injection technique using insulin syringes. After baseline assessment, patients were treated for successive 2-month periods with daily bedtime injections of GHRP-2 in doses of 0.3, 1.0, and 3.0 µg/kg. During a final 2-month period, patients received both 3.0 µg/kg GHRP-2 and 3.0 µg/kg GHRH at separate injection sites. Patients and parents were instructed to report any side effects and remained in frequent contact with study personnel.
You want to read a study where a GHRP was used orally? Here is an abstract where GHRP-6 was given orally. Note the dose 300mcg/kg which means 30mg for a 100kg man. You do realize that the retail price of a single dose using this protocol would mean about $300.
The result was less GH release than that illicited by GHRP-6 given subcutaneously at 1mcg/kg or 100mcg....which by-the-way is 300 times smaller than the dose given here by oral administration.
Here is the abstract:
European Journal of Endocrinology, Vol 133, Issue 4, 425-429
Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature
Growth hormone-releasing peptide 6 (GHRP-6) is a synthetic hexapeptide with a potent GH-releasing activity after intravenous, subcutaneous, intranasal and oral administration in man. Previous data showed its activity also in some patients with GH deficiency. The aim of our study was to verify the GH-releasing activity of oral GHRP-6 administration on GH secretion in children with normal short stature.
The effect of oral GHRP-6 (300 micrograms/kg) was compared with that of the maximally effective dose of intravenous GH-releasing hormone (GHRH-29, 1 microgram/kg). As the GHRH-induced GH rise in children is potentiated by arginine (ARG), even when administered by oral route at low dose (4 g), we studied also the interaction of oral GHRP-6 and ARG administration.
We studied 13 children (nine boys and four girls aged 6.2-10.5 years, pubertal stage I) with normal short stature (height less than -2 SD score; height velocity more than -2 SD score; normal bone age; insulin-like growth factor I > 70 micrograms/l).
In a first group of children (N = 7), oral GHRP-6 administration induced a GH response (mean +/- SEM; peak at 60 min vs baseline: 18.8 +/- 3.0 vs 1.1 +/- 0.3 micrograms/l, p < 0.0006; area under curve: 1527.3 +/- 263.9 micrograms l-1 h-1) which was similar to that elicited by GHRH (peak at 45 min vs baseline: 20.8 +/- 4.5 vs 2.2 +/- 0.9 micrograms/l, p < 0.007; area under curve: 1429.4 +/- 248.2 micrograms l-1 h-1).(ABSTRACT TRUNCATED AT 250 WORDS)
For you... drinking Hemogex of course.
Originally Posted by dieselken77